<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505828</url>
  </required_header>
  <id_info>
    <org_study_id>93612</org_study_id>
    <secondary_id>2014-A01561-46</secondary_id>
    <nct_id>NCT02505828</nct_id>
  </id_info>
  <brief_title>ARTEMIS Synovial Markers in Arthritis Childhood</brief_title>
  <acronym>ARTEMIS</acronym>
  <official_title>ARTEMIS Synovial Markers in Arthritis Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to find markers that could differentiate infectious and inflammatory&#xD;
      arthritis. The investigators want to find markers by differential analysis by compare&#xD;
      synovial fluids of septic and inflammatory arthritis. The investigators will use for this&#xD;
      analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The&#xD;
      investigators will use one marker or a score with biological and clinical data to&#xD;
      discriminate arthritis of infectious and inflammatory etiology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis.</measure>
    <time_frame>1 day</time_frame>
    <description>Identify blood sampling biomarkers of Arthritis childhood</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Septic Arthritis</condition>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Septic arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>with bacteriological identification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvenile idiopathic arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>beyond the ILAR (International League of Associations for Rheumatology) definition</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Articular punction, salivary samples, blood sample</intervention_name>
    <arm_group_label>Juvenile idiopathic arthritis</arm_group_label>
    <arm_group_label>Septic arthritis</arm_group_label>
    <other_name>Proteomic analysis</other_name>
    <other_name>Cytokine dosage</other_name>
    <other_name>Monocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Septic arthritis with bacteriological identification&#xD;
&#xD;
          -  Juvenile idiopathic arthritis beyond the ILAR definition&#xD;
&#xD;
          -  Having acute arthritis requiring an articular draining&#xD;
&#xD;
          -  Child benefiting from a national insurance scheme&#xD;
&#xD;
          -  Collection of the consent of the parents or the legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins&#xD;
             lower than 70 %, activated partial thromboplastin times (APTT)&gt; 1,5&#xD;
&#xD;
          -  Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding&#xD;
             the articular draining.&#xD;
&#xD;
          -  Treatment by antibiotic begun more than 24 hours before the draining.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric EJ JEZIORSKI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Nziza N, Jeziorski E, Delpont M, Cren M, Chevassus H, Carbasse A, Mahe P, Abassi H, Joly-Monrigal P, Schordan E, Mangé A, Jorgensen C, Apparailly F, Duroux-Richard I. Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis. Cells. 2019 Nov 26;8(12). pii: E1521. doi: 10.3390/cells8121521.</citation>
    <PMID>31779271</PMID>
  </results_reference>
  <results_reference>
    <citation>Cren M, Nziza N, Carbasse A, Mahe P, Dufourcq-Lopez E, Delpont M, Chevassus H, Khalil M, Mura T, Duroux-Richard I, Apparailly F, Jeziorski E, Louis-Plence P. Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis. Front Immunol. 2020 Jul 31;11:1716. doi: 10.3389/fimmu.2020.01716. eCollection 2020.</citation>
    <PMID>32849606</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>septic</keyword>
  <keyword>Juvenile idiopathic arthritis</keyword>
  <keyword>diagnosis</keyword>
  <keyword>proteomic</keyword>
  <keyword>cytokine</keyword>
  <keyword>monocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

